Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease. (PubMed, Cureus) - Sep 6, 2026 - "Given upadacitinib's established efficacy for both HS and CD, the drug was continued, and topical augmented betamethasone dipropionate was initiated, achieving adequate control at two-week follow-up...Comparable psoriasiform eruptions have been reported with baricitinib and tofacitinib, primarily in rheumatoid arthritis, a comorbidity present in our patient and an important interpretive caveat...Paradoxically, upadacitinib has also resolved psoriasiform eruptions in HS, underscoring the bidirectional and unpredictable nature of JAK1 inhibitor-mediated immune modulation. Psoriasiform dermatitis may represent a paradoxical cutaneous reaction to upadacitinib in patients with HS, warranting vigilant dermatologic monitoring and further investigation into individual susceptibility factors."
Journal • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Hidradenitis Suppurativa • Immune Modulation • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Psoriasis • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • IFNG • STAT1
|
|
Alma Cruz; Cristina P Gerena-Maldonado; Gerardo S Caussade-Silvestrini; Julio E Sánchez; Natalia A Alvarado-Ramos; Rafael E Rodríguez-Rivera
|